瑞康医药: 第五届董事会第十八次会议决议的公告

Core Points - The company held its 18th meeting of the 5th Board of Directors on September 5, 2025, with all 8 directors present, and the meeting was conducted in accordance with relevant laws and regulations [1] - The Board approved the revision of the company's articles of association to align with the latest legal requirements and the company's development strategy, with a unanimous vote of 8 in favor [1] - The Board also approved the revision of certain governance systems to enhance the company's governance structure, again with a unanimous vote of 8 in favor [2] - The company proposed a guarantee limit for itself and its subsidiaries totaling no more than RMB 2 billion, with specific limits based on the subsidiaries' asset-liability ratios, which was also approved unanimously [3] - A proposal to convene the 2025 first extraordinary general meeting was approved with a unanimous vote of 8 in favor [3]